Journal Home
Search for

Volume 74, Issue 1, Pages 47-54 (1 May 2009)


View previous. 8 of 51 View next.

Dose–Response Relationship for Image-Guided Stereotactic Body Radiotherapy of Pulmonary Tumors: Relevance of 4D Dose Calculation

Matthias Guckenberger, M.D.Corresponding Author Informationemail address, Joern Wulf, M.D., Gerd Mueller, M.D., Thomas Krieger, M.Sc., Kurt Baier, M.Sc., Manuela Gabor, M.S., Anne Richter, M.Sc., Juergen Wilbert, Ph.D., Michael Flentje, M.D.

Received 3 April 2008; received in revised form 11 June 2008; accepted 12 June 2008. published online 31 October 2008.

Purpose

To evaluate outcome after image-guided stereotactic body radiotherapy (SBRT) for early-stage non–small-cell lung cancer (NSCLC) and pulmonary metastases.

Methods and Materials

A total of 124 patients with 159 pulmonary lesions (metastases n = 118; NSCLC, n = 41; Stage IA, n = 13; Stage IB, n = 19; T3N0, n = 9) were treated with SBRT. Patients were treated with hypofractionated schemata (one to eight fractions of 6–26 Gy); biologic effective doses (BED) to the clinical target volume (CTV) were calculated based on four-dimensional (4D) dose calculation. The position of the pulmonary target was verified using volume imaging before all treatments.

Results

With mean/median follow-up of 18/14 months, actuarial local control was 83% at 36 months with no difference between NSCLC and metastases. The dose to the CTV based on 4D dose calculation was closely correlated with local control: local control rates were 89% and 62% at 36 months for >100 Gy and <100 Gy BED (p = 0.0001), respectively. Actuarial freedom from regional and systemic progression was 34% at 36 months for primary NSCLC group; crude rate of regional failure was 15%. Three-year overall survival was 37% for primary NSCLC and 16% for metastases; no dose–response relationship for survival was observed. Exacerbation of comorbidities was the most frequent cause of death for primary NSCLC.

Conclusions

Doses of >100 Gy BED to the CTV based on 4D dose calculation resulted in excellent local control rates. This cutoff dose is not specific to the treatment technique and protocol of our study and may serve as a general recommendation.

 Department of Radiation Oncology, Julius-Maximilians University, Wuerzburg, Germany

 Department of Radiooncology, Lindenhofspital, Bern, Switzerland

Corresponding Author InformationReprint requests to: Dr. Matthias Guckenberger, Department of Radiation Oncology, University of Wuerzburg, Josef-Schneider-St. 11, 97080 Wuerzburg, Germany. Tel: (+49) 931-201-28884; Fax: (+49) 931-201-28221

 Conflict of interest: none.

PII: S0360-3016(08)03053-8

doi:10.1016/j.ijrobp.2008.06.1939


View previous. 8 of 51 View next.